CORMORANT PHARMACEUTICALS
Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver of malignant tumors, HuMax-IL8 was acquired from Genmab A/S and taken into development by Cormorant. HuMax-IL8, is a fully human monoclonal antibody
CORMORANT PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2010-01-01
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Total Employee:
1+
Status:
Active
Similar Organizations
Erimos Pharmaceuticals
Erimos Pharmaceuticals is a biopharmaceutical company
Learmont Pharmaceuticals
Learmont Pharmaceuticals is a pharmaceutical company.
Tzana Pharmaceuticals
Tzana Pharmaceuticals is a pharmaceutical company.
More informations about "Cormorant Pharmaceuticals"
Cormorant Pharmaceuticals - Crunchbase Company …
Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based …See details»
Bristol-Myers Squibb buys cancer, rare disease biotech Cormorant
Jul 5, 2016 The rights to the drug originally came from a deal Cormorant struck with Copenhagen-based Genmab back in 2012, who itself bought the drug from Medarex in 2007- …See details»
Cormorant Pharmaceuticals AB - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cormorant Pharmaceuticals AB of Solna, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»
Cormorant Pharmaceuticals - LinkedIn
Cormorant Pharmaceuticals is a recently founded biopharmaceutical company focusing on the development of therapeutics for the treatment of cancer and rare diseases.See details»
Cormorant Pharmaceuticals - Products, Competitors, Financials ...
It recently acquired Cormorant Pharmaceuticals in an all-stock transaction with the deal worth up to $520 million to boost and strengthen its immuno-oncology pipeline. With this acquisition, it …See details»
Cormorant Pharmaceuticals AB - Företagsinformation - allabolag.se
Cormorant Pharmaceuticals AB,556821-3853 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Cormorant …See details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of …See details»
Cormorant Pharmaceuticals AB - Company Profile and News
Company profile page for Cormorant Pharmaceuticals AB including stock price, company news, executives, board members, and contact informationSee details»
Cormorant Pharmaceuticals AB - Drug pipelines, Patents, Clinical …
Explore Cormorant Pharmaceuticals AB with its drug pipeline, therapeutic area, technology platform, 8 news.See details»
Bristol-Myers Squibb acquires Cormorant …
Jul 5, 2016 Cormorant Pharmaceuticals is a private, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to …See details»
Cormorant Pharmaceuticals - PitchBook
Cormorant Pharmaceuticals General Information Description. Provider of pharmaceutical services. The company primarily focuses on developing therapeutics and related services for cancer and other rare diseases.See details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 NEW YORK & STOCKHOLM--(BUSINESS WIRE)--Bristol-Myers Squibb Company(NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers …See details»
BMS Buys Cormorant Pharmaceuticals for Up to $520M
Jul 6, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a Sweden-based developer of cancer and rare-disease therapies, for up to $520 million, in a deal …See details»
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
Jul 5, 2016 About Cormorant Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the …See details»
BMS Acquires Cormorant Pharmaceuticals for Up to $520M
Jul 5, 2016 Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a developer of cancer and rare-disease therapies, for up to $520 million, in a deal designed to broaden the …See details»
Bristol-Myers Squibb buys rare disease biotech Cormorant …
Jul 6, 2016 Bristol-Myers Squibb is to buy Cormorant Pharmaceuticals in a deal which could be worth up to $520m. Under the deal, Bristol-Myers Squibb has acquired all of the outstanding …See details»
Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential
Jul 5, 2016 Bristol-Myers Squibb has bought Swedish firm Cormorant Pharmaceuticals in a potentially $520 million deal, adding an antibody program designed to boost the efficacy of …See details»
Cormorant Pharmaceuticals Acquired by BMS for $520M
Jul 11, 2016 Cormorant Pharmaceuticals, developer of cancer and disease therapies, has been acquired by Bristol-Myers Squibb in a move to expand BMS pipelines. ... Cormorant acquired …See details»
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jul 5, 2016 Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska …See details»
FDA to pharmaceutical companies: Certain studies conducted by …
3 days ago FDA has identified significant data integrity and study conduct concerns with bioequivalence and bioavailability studies conducted by Raptim Research Pvt. Ltd., a contract …See details»